enGene Holdings Inc. (ENGNW)

NASDAQ: ENGNW · Real-Time Price · USD · Warrants
1.300
-0.200 (-13.33%)
Nov 10, 2025, 4:00 PM EST - Market closed
-13.33%
Market Cap307.66M
Revenue (ttm)n/a
Net Income (ttm)-94.72M
Shares Out 51.19M
EPS (ttm)-1.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume776
Open1.300
Previous Close1.500
Day's Range1.300 - 1.300
52-Week Range0.510 - 3.800
Beta-0.26
Analystsn/a
Price Targetn/a
Earnings Daten/a

About ENGNW

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Ronald H. Cooper
Employees 57
Stock Exchange NASDAQ
Ticker Symbol ENGNW
Full Company Profile

News

There is no news available yet.